PubMed · last 30 days

Peptide research index

An automated bibliographic list from NCBI E-utilities (PubMed). It is not medical advice, not a review, and not an interpretation of results. Records are grouped by search term. Only title, journal, publication date, first author, and the PubMed link are shown.

Source: PubMed via esearch and esummary, database pubmed, sorted by date, approximately forty records across the listed compounds. This page refreshes weekly. Compounds: BPC-157, thymosin beta-4, semaglutide, tirzepatide, retatrutide, cagrilintide, ipamorelin, sermorelin, GHRP-6.

16 records · fetched 2026-10-16 UTC

Semaglutide

Changes in Gait Speed During a 12-Month Multidisciplinary Obesity Management Program Including Semaglutide: A Real-World Observational Study in Japanese Adults With Musculoskeletal Disorders.
Internal medicine (Tokyo, Japan) · 2026 Oct 15 · Tomita M et al.
Early Uptake of Oral Semaglutide for Obesity Treatment After Regulatory Approval.
Annals of internal medicine · 2026 Oct 13 · Jelwan Y et al.
Characterizing the Adverse Event Profile of Semaglutide: A Comprehensive U.S. Food and Drug Administration Adverse Event Reporting System-Based Pharmacovigilance Study.
Clinical nutrition ESPEN · 2026 Oct 12 · Thawkar SA et al.
Weight Maintenance Following Discontinuation of Semaglutide in an Adolescent with Antipsychotic-Associated Weight Gain: A Case Report.
Hormone research in paediatrics · 2026 Oct 12 · Griffing E et al.
Semaglutide in Heart Failure with Preserved Ejection Fraction and Obesity: The Gap Between Discussion and Use.
Cardiology · 2026 Oct 12 · Jurin I et al.
Severe Euglycemic Diabetic Ketoacidosis After Semaglutide-Associated Poor Intake Despite Empagliflozin Discontinuation: A Case Report.
International medical case reports journal · 2026 Oct 6 · Niknam K et al.
Indication-specific adverse event profiles of semaglutide and liraglutide: a FAERS disproportionality analysis.
Frontiers in pharmacology · 2026 Sep 29 · Fisch SA et al.
Cardiometabolic therapy for rhythm control: a case report of refractory atrial fibrillation resolving after initiation of semaglutide for obesity.
European heart journal. Case reports · 2026 Sep 28 · Weitkamp FM et al.
Advances in pharmacologic management of obesity: oral semaglutide for weight management.
Annals of medicine and surgery (2012) · 2026 Sep 8 · Zainab F et al.

Tirzepatide

Outcomes in patients with diabetes, atherosclerotic cardiovascular disease, and heart failure treated with tirzepatide or dulaglutide: SURPASS-CVOT analysis.
European journal of preventive cardiology · 2026 Oct 15 · Nicholls SJ et al.
Real-World Treatment Patterns and Weight Outcomes Before and After a Tirzepatide Price Increase in Over One Million Self-Paying UK Adults With Overweight or Obesity.
Diabetes, obesity & metabolism · 2026 Oct 14 · Dix S et al.
Effects of tirzepatide (GIP/GLP-1 dual receptor agonist) on cardiorenal biomarkers and functional capacity in heart failure: a systematic review and meta-analysis.
The Journal of clinical endocrinology and metabolism · 2026 Oct 13 · Eisa N et al.
Tirzepatide use in adolescents with metabolic dysfunction-associated steatotic liver disease (MASLD): A case series.
JPGN reports · 2026 Oct 12 · Perumpail BJ et al.
Values, preferences, and treatment burden for initiation of GLP-1 receptor agonists, SGLT-2 inhibitors, tirzepatide, and finerenone in adults with type 2 diabetes: systematic review.
BMJ medicine · 2026 Oct 8 · González-Cruz DC et al.
Pancreatic and biliary safety signals of GLP-1 receptor agonists and tirzepatide: a disproportionality analysis of FAERS reports.
Frontiers in endocrinology · 2026 Sep 28 · Wu Y et al.

Retatrutide

Self-Reported Adverse Effects Among Social Media Users Taking Nonapproved Retatrutide.
JAMA network open · 2026 Oct 1 · Sehgal NKR et al.